anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
The invention discloses a medicine for treating breast hyperplasia angiitis and relates to a Chinese herbal medicine. The medicine is characterized in that the medicine is prepared by the following raw materials of certain weight portions: 980 to 1200 portions of long-stored carbonized petiole of windmill palm, 80 to 120 portions of urine sediment and 0.05 to 0.15 portion of cabardine. When being prepared, the materials are ground into fine powder. The medicine uses urine sediment with heavy material that can clear heat, lower evil fire and remove blood stasis and the supplementary materials of long-stored carbonized petiole of windmill palm that can astringe to arrest bleeding and cabardine of resuscitation and dredging channel, thus achieving the effect of relieving stuffiness and regulating qi, breaking and removing blood stasis, activating blood and relieving pain, clearing heat-toxin, disinfection and detumescence and promoting granulation and healing wound. The medicine has obvious effect. The medicine has the advantages of convenient material selecting, simple preparation, good effect, no toxicity and side effect and low cost. As is proved by clinical research of 185 patients, the total effective rate is 97.2 percent.
Deltamethrin (DM) is a widely used insecticide that has demonstrated developmental toxicity in the early life stages of fish. To better characterize the underlying mechanisms, embryos from Tg(cmlc2:RFP), Tg(apo14:GFP), and Tg(mpx:GFP) transgenic strains of zebrafish were exposed to nominal DM concentrations of 0.1, 1, 10, 25, and 50 μg/L until 120 h post-fertilization (hpf). Heart size increased 56.7%, and liver size was reduced by 17.1% in zebrafish exposed to 22.7 and 24.2 μg/L DM, respectively. RNA sequencing and bioinformatic analyses predicted that key biological processes affected by DM exposure were related to inflammatory responses. Expression of IL-1 protein was increased by 69.0% in the 24.4 μg/L DM treatment, and aggregation of neutrophils in cardiac and hepatic histologic sections was also observed. Coexposure to resatorvid, an anti-inflammatory agent, mitigated inflammatory responses and cardiac toxicity induced by DM and also restored liver biomass. Our data indicated a complex proinflammatory mechanism underlying DM-induced cardiotoxicity and hepatotoxicity which may be important for key events of adverse outcomes and associated risks of DM to early life stages of fish.
The present study aims to investigate the clinical efficacy of recombinant human growth hormone (r-hGH) in the treatment of school-age pediatric patients with idiopathic short stature (ISS). Pediatric patients who were diagnosed with ISS and treated with r-hGH at our hospital were enrolled as research subjects. The main outcome indicators included the serum level of insulin-like growth factor-1, insulin-like growth factor binding protein-3, baseline height standard deviation scores, and posttreatment height standard deviation scores and retrospective analysis was performed. This study complies with the Strengthening the Reporting of Observational Studies in Epidemiology guidelines. A total of 42 pediatric patients with a diagnosis of ISS were enrolled in the present study (24 males and 18 females). Following treatment, the levels of insulin-like growth factor-1 and insulin-like growth factor binding protein-3 were significantly higher than the baseline level and the difference was statistically significant. The posttreatment height standard deviation scores was significantly higher than the baseline height standard deviation scores and the difference was statistically significant. There were no significant differences between male and female participants in height standard deviation scores, either before or following treatment. This study found that r-hGH therapy may increase height in school-age pediatric patients with ISS and is therefore worthy of clinical application.
FIELD: medicine, pharmaco-therapy, phytotherapy. SUBSTANCE: invention relates to preparing agents showing the simultaneous antiopisthorchiasis and antilambliasis effect and for treatment of patients with opisthorchiasis, lambliasis and combined opisthorchiasis-lambliasis parasites. Medicinal species consists of berry dried leaves and rose dried fruits. Invention proposes the schedule of treatment of patients with opisthorchiasis and lambliasis using the proposed medicinal species. EFFECT: attenuation of adverse effects caused by known antiopisthorchiasis and antilambliasis agents. 4 cl, 3 ex
All participants will complete a pre-course survey, engage in the online educational intervention, then complete 2 post-course surveys. They have the option to provide urine samples before and after the intervention.
ABSTRACT      At least seven genes have been identified which encode proteins generally identified as pregnancy specific protein (SP1), also known as pregnancy specific beta glycoprotein (PSBG).  These genes have been found using human placental SP1 labelled cDNA in a number of mammalian species, including human, baboon, cow, sheep, goat, pig and rat, and non-mammalian species, including fish and bird.  The genes are classified on the basis of their nucleotide sequence, structure, glycosylation sites, restriction enzyme mapping, and tissue of origin.  Genes have been found in cells of human placenta origin (three groups); in intestinal cells; in cells of both testis and placental origin; in tissue of testis origin; and in HeLa cells.  One clone encodes a SP1-like protein which is specifically found in placenta and appears to have a hydrophobic C-terminal region, indicating that it is membrane bound.  These cDNAs are at least 65% homologous with some members of the immunoglobulin gene superfamily such as CEA.  Methods for making and using the DNA sequences, proteins, and antibodies to the proteins are also described, particularly for diagnostic work.          Immunosuppressive activity and growth promoting activities have also been demonstrated by suppression of lymphocyte proliferation and inducement of megakaryocytopoiesis, respectively.
OBJECTIVE: Ultrasound transient elastography (TE) technologies for liver stiffness measurement (LSM) utilize vibration of small, flat pistons, which generate shear waves that lack directivity. The most common cause for LSM failure in practice is insufficient shear wave signal at the needed depths. We propose to increase shear wave amplitude by focusing the waves into a directional beam. Here, we demonstrate the generation and propagation of focused shear wave beams (fSWBs) in gelatin.
METHODS: Directional fSWBs are generated by vibration at 200-400 Hz of a concave piston embedded near the surface of gelatin phantoms and measured with high-frame-rate ultrasound imaging. Five phantoms with a range of stiffnesses are employed. Shear wave speeds assessed by fSWBs are compared with those by radiation-force-based methods (2D SWE). fSWB amplitudes are compared to predictions using an analytical model.
RESULTS: fSWB-derived shear wave speeds are in good agreement with 2D SWE. The amplitudes of fSWBs are localized to the LSM region and are significantly greater than unfocused shear waves. Overall agreement with theory is observed, with some discrepancies in the theoretical source condition.
CONCLUSION: Focusing shear waves can increase the signal in the LSM region for TE. Challenges for translation include coupling piston vibration with the patient skin and increased attenuation in vivo compared to the phantoms employed here.
SIGNIFICANCE: Fibrosis is the most predictive measure of patient outcome in non-alcoholic fatty liver disease. Increased shear wave amplitude in the LSM region can reduce fibrosis assessment failure rates by TE, thus reducing the need for invasive methods like biopsy.
A syndrome consisting of acute myopia associated with secondary angle closure glaucoma has been reported in patients receiving TOPAMAX®. Symptoms include acute onset of decreased visual acuity and/or ocular pain. Ophthalmologic findings can include myopia, anterior chamber shallowing, ocular hyperemia (redness) and increased intraocular pressure. Mydriasis may or may not be present. This syndrome may be associated with supraciliary effusion resulting in anterior displacement of the lens and iris, with secondary angle closure glaucoma. Symptoms typically occur within 1 month of initiating TOPAMAX® therapy. In contrast to primary narrow angle glaucoma, which is rare under 40 years of age, secondary angle closure glaucoma associated with topiramate has been reported in pediatric patients as well as adults. The primary treatment to reverse symptoms is discontinuation of TOPAMAX® as rapidly as possible, according to the judgment of the treating physician. Other measures, in conjunction with discontinuation of TOPAMAX®, may be helpful.

Elevated intraocular pressure of any etiology, if left untreated, can lead to serious sequelae including permanent vision loss.
Partial denture wearers are at higher risk of developing caries and periodontal disease. Thus, providing oral and denture hygiene care instructions after denture delivery is crucial for prevention of oral diseases. A mobile application was developed using the progressive web application technology for chairside education and to serve as a reference material. The effect of the mobile application on patient's dental knowledge compared to the conventional method was evaluated using a knowledge questionnaire administered before and after education. The knowledge scores obtained were analysed using the Two-way mixed ANOVA test. Patients' oral hygiene was assessed by comparing the Silness and Loe Plaque Index and Gingival Index scores before and after education. Denture hygiene was evaluated by comparing the denture plaque score before and after education. Statistical analysis of the Plaque Index, Gingival Index and denture plaque score was done using Mann-Whitney U Test and Friedman Test.
A pharmacologically active composition which is suitable for use in palliati ve cancer therapy and as an agent having a muscle-relaxing and/or analgetic effect in neurological diseases. Said composition contains at least 80 wt. % , preferably 90 wt. %, tetrahydrocannabinol (THC) and cannabidiol (CBD), in relation to the overall weight of cannabinoids present therein. The weight ratio of THC to CBD = 75:25 - 20:80, preferably 3:1 - 1:2, and especially 2: 1. Said composition can be used for the production of pharmacologically effecti ve agents which can be used in palliative cancer therapy and in the treatment o f neurological diseases.
Drought poses significant risks to maize cultivation by impairing plant growth, water uptake and yield; nano priming offers a promising avenue to mitigate these effects by enhancing plant water relations, stress tolerance and overall productivity. In the current experiment, we tested a hypothesis that seed priming with iron oxide nanoparticles (n-Fe2O3) can improve maize performance under water stress by improving its growth, water relations, yield and biochemical attributes. The experiment was conducted on a one main plot bisected into two subplots corresponding to the water and drought environments. Within each subplot, maize plants were raised from n-Fe2O3 primed seeds corresponding to 0 mg. L- 1 (as control treatment), 25, 50, 75, and 100 mg. L- 1 (as trial treatments). Seed priming with n-Fe2O3 at a concentration of 75 mg. L- 1 improved the leaf relative water content, water potential, photosynthetic water use efficiency, and leaf intrinsic water use efficiency of maize plants by 13%, 44%, 64% and 17%, respectively compared to control under drought stress. The same treatments improved plant biochemical attributes such as total chlorophyll content, total flavonoids and ascorbic acid by 37%, 22%, and 36%, respectively. Seed priming with n-Fe2O3 accelerated the functioning of antioxidant enzymes such as SOD and POD and depressed the levels of leaf malondialdehyde and hydrogen peroxide significantly. Seed priming with n-Fe2O3 at a concentration of 75 mg. L- 1 improved cob length, number of kernel rows per cob, and 100 kernel weight by 59%, 27% and 33%, respectively, under drought stress. Seed priming with n-Fe2O3 can be used to increase maize production under limited water scenarios.
Participants attend financial health educational program over 60 minutes. Patients also receive educational materials on study.
The present application relates generally to emulsifiers and methods of production thereof, and specifically to emulsifiers prepared using renewable and/or agricultural products through a physical process. Flour of cereal grains, legumes, or other plant materials contains both protein and carbohydrate, in particular starch. The preparation procedure of flour emulsifier contains physical processing, including but not limited to specifically designed heating, milling, or the combinations of both. Emulsions of lipophilic materials are prepared using flour emulsifiers. The emulsions formed can be further dehydrated using spray drying, drum drying, freeze drying, vacuum drying, or other drying methods. The emulsions prepared using flour emulsifiers as well as their dehydrated products show enhanced stability against physical and chemical deteriorations as compared with those prepared using conventional emulsifiers, such as octenylsuccinate starch and gum arabic.
Cohorts/participants in the no intervention arm do not receive either the in-person education or the app. However, after completing the 10 month survey, they will have access to the app and will be invited to participate in the in-person program after the study implementation phase is completed (years 4 and 5).
PURPOSE: A composition containing Citrus junos sieb extract is provided to prevent or treat various heart diseases and to protect cardiomyocytes. CONSTITUTION: A pharmaceutical composition for preventing or treating cariomyocytes contains Citrus junos sieb extract as an active ingredient. The extract is an organic solvent extract or water extract. The organic solvent is low alcohol of C1-C4. A health food for relieving myocardial infarction contains the extract as an active ingredient. The pharmaceutical composition is manufactured in the form of a tablet, pill, powder, granules, and capsule. The dose of the extract is 10-3,000 mg/kg.
A composition which contains mixed herbal extracts is provided to ensure excellent stability, prevent hair loss and promote hair growth. A cosmetic composition for preventing hair loss and promoting hair growth comprises 0.01-5 weight% of mixed herbal extracts of Rehmannia glutinosa Libschitz var. purpurea Makino, Polygonum multiflorum THUNB., and Dioscoria tenuipes FR. et SAV. as an active ingredient. The mixed herbal extracts is isolated using water, low alcohol solvent or mixture of methanol, ethanol, and butanol, hexane, butyleneglycol, propyleneglycol, glycerin, acetic acid ethyl, ether, and chloroform. The mixed herbal extract comprises the Rehmannia glutinosa Libschitz var. purpurea Makino, Polygonum multiflorum THUNB., and Dioscoria tenuipes FR. et SAV. in a ratio of 1-10 : 1-5 : 1-5. The composition is used in a form of hair tonic, hair conditioner, hair essence, hair lotion, hair nutrition lotion, hair shampoo, hair rinse, hair treatment, hair cream, hair aerosol and hair soap.
Methods are provided to improve the positive predictive value for cancer detection using cell-free nucleic acid samples. Various embodiments are directed to applications (e.g., diagnostic applications) of the analysis of the fragmentation patterns and size of cell-free DNA, e.g., plasma DNA and serum DNA, including nucleic acids from pathogens, including viruses. Embodiments of one application can determine if a subject has a particular condition. For example, a method of present disclosure can determine if a subject has cancer or a tumor, or other pathology. Embodiments of another application can be used to assess the stage of a condition, or the progression of a condition over time. For example, a method of the present disclosure may be used to determine a stage of cancer in a subject, or the progression of cancer in a subject over time (e.g., using samples obtained from a subject at different times).
NEW MATERIAL:A human immunoglobulin that binds with a stomach cancer cell strains, MKN-1, MKN-45 and KATO-III, lung cancer cell strains, PC-10 and PC-14, but does not to hematopoietic cell strains, CCRF-CEM and U-937. USE:Diagnostic agent and remedy for stomach and lung cancers. PREPARATION:Lymph nod cells are collected by extracting lymph nods near the area affected by stomach cancer in a patient surgerical operation and by fragmenting the nods. After proliferation, the cells are combined with the B-cell strain, ATCC.CRL-8118 and poured into individual wells on microplates and cultured. Then, the wells which have formed colonies are transferred to cultivation plates to effect propagation. Further, the supernatant of the cultivation mixture is added to each well on a microplate into which the target cells are poured to effect the reaction. Then, the strains reactive with the cancer cells are selected and cloned and cultivated to obtain a human imminoglobulin reactive with cancer cells.
<P>PROBLEM TO BE SOLVED: To provide a feces odor improving composition formed from dried bonito.  <P>SOLUTION: A feces odor improving composition composed mainly of a resistant protein derived from dried bonito is continuously ingested. Metabolic products emitting foul odor such as indole and skatole in feces are decreased by the method to decrease the foul odor of the feces. The feces odor improving composition has a solid state and is produced by the enzymatic decomposition of dried bonito. The feces odor is easily and safely improved by the composition to reduce the labor of an aged person and a caretaker for the home care in the healthcare for the elderly in an aging society. The composition is effective also for decreasing the foul odor of pet feces.  <P>COPYRIGHT: (C)2006,JPO&NCIPI
INTRODUCTION: Machine perfusion can enable isolated support of composite tissues, such as free flaps. The goal of perfusion in this setting is to preserve tissues prior to transplantation or provide transient support at the wound bed. This study aimed to establish a rodent model of machine perfusion in a fasciocutaneous-free flap to serve as an affordable testbed and determine the potential of the developed support protocol to deter ischemia-related metabolic derangement.
METHODS: Rat epigastric-free flaps were harvested and transferred to a closed circuit that provides circulatory and respiratory support. Whole rat blood was recirculated for 8 h, while adjusting the flow rate to maintain arterial-like perfusion pressures. Blood samples were collected during support. Extracellular tissue lactate and glucose levels were characterized with a microdialysis probe and compared with warm ischemic, cold ischemic, and anastomosed-free flap controls.
RESULTS: Maintenance of physiologic arterial pressures (85-100 mmHg) resulted in average pump flow rates of 360-430 μL/min. Blood-based measurements showed maintained glucose and oxygen consumption throughout machine perfusion. Average normalized lactate to glucose ratio for the perfused flaps was 5-32-fold lower than that for the warm ischemic flap controls during hours 2-8 (P < 0.05).
CONCLUSIONS: We developed a rat model of ex vivo machine perfusion of a fasciocutaneous-free flap with maintained stable flow and tissue metabolic activity for 8 h. This model can be used to assess critical elements of support in this setting as well as explore other novel therapies and technologies to improve free tissue transfer.
PURPOSE: This study aims to investigate how the type of anesthesia used during major orthopedic surgery may impact adverse short-term postoperative outcomes depending on frailty.
METHODS: To conduct this investigation, we recruited individuals aged 65 years and older who underwent major orthopedic surgery between March 2022 and April 2023 at a single institution. We utilized the FRAIL scale to evaluate frailty. The primary focus was on occurrences of death or the inability to walk 60 days after the surgery. Secondary measures included death within 60 days; inability to walk without human assistance at 60 days; death or the inability to walk without human assistance at 30 days after surgery, the first time out of bed after surgery, postoperative blood transfusion, length of hospital stay, hospital costs, and the occurrence of surgical complications such as dislocation, periprosthetic fracture, infection, reoperation, wound complications/hematoma.
RESULTS: In a study of 387 old adult patients who had undergone major orthopedic surgery, 41.3% were found to be in a frail state. Among these patients, 262 had general anesthesia and 125 had neuraxial anesthesia. Multifactorial logistic regression analyses showed that anesthesia type was not linked to complications. Instead, frailty (OR 4.04, 95% CI 1.04 to 8.57, P< 0.001), age (OR 1.05, 95% CI 1.00-1.10, P= 0.017), and aCCI scores, age-adjusted Charlson Comorbidity Index, (OR 1.36, 95% CI 1.12 to 1.66, P= 0.002) were identified as independent risk factors for death or new walking disorders in these patients 60 days after surgery. After adjusting for frailty, anesthesia methods was not associated with the development of death or new walking disorders in these patients (P > 0.05).
CONCLUSION: In different frail populations, neuraxial anesthesia is likely to be comparable to general anesthesia in terms of the incidence of short-term postoperative adverse outcomes.
The usual care group will receive remote blood pressure monitoring for approximately 6 weeks via the clinical home blood pressure monitoring program at Magee Women's Hospital of UPMC and be discharged after delivery as usual. This monitoring is standardly offered to women post-delivery with hypertensive disorders of pregnancy. Participants will text in their blood pressures to the medical record systems and be monitored by clinical staff.
PURPOSE: A food additive composition for prevention of type B hepatitis containing an ellagic acid derivative as an effective ingredient is provided. It possesses low cytotoxicity and inhibits e antigen secretion which maintaining hepatitis in chronic state without affecting the activity of a hepatitis virus DNA polymerase and thus can be used in diet therapy for a chronic hepatitis patient. CONSTITUTION: The food additive composition for prevention of type B hepatitis contains an ellagic acid derivative having the structure of the formula(1) or pharmaceutically acceptable salts as an effective ingredient. In formula, R1, R2, R3 and R4 are each independent H, OH or C1-3 alkoxy groups. The desirable ellagic acid derivative is ellagic acid of the formula(2). In formula, R1, R2, R3 and R4 are OH. For an example, 0.24 to 0.64% by weight of ellagic acid is mixed with 20% by weight of a gum base, 76.36 to 76.76% by weight of sugar, 1% by weight of fruits flavors and 2% by weight of water to give chewing gum.
An incense burner and storage device includes a lower housing with a base and a storage compartment. The device also includes an upper housing and an upwardly extending column for supporting the upper housing. The upper housing includes a support for charcoal and incense and an ashtray for collecting ashes. The ashtray is also rotatable about a vertical axis between a loading position and a burning position. The ashtray also includes a perforated screen-like bottom that allows a flame to pass therethrough. A cigarette lighter is used for heating the charcoal and is pivotally mounted within the column for removal and replacement of the lighter. An adjustment mechanism is fixed to one side of the upper portion of the column and allows the charcoal and incense support to be raised or lowered with respect to the cigarette lighter.